SEC Form 4 · accession 0001209191-15-084684
BG Medicine, Inc. · BGMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Noubar Afeyan
Director · 10% Owner
Period of report
Dec 9, 2015
Accepted (ET)
Dec 11, 2015 · 4:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001407038
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 9, 2015 | S | 43,930 | $0.56 | D | 0 | D | |
| Common StockF2,F3 | Dec 9, 2015 | S | 2,508 | $0.56 | D | 0 | I | Held by Atlast LP |
| Common StockF4 | holding | — | — | — | 58,232 | I | Held by AGTC Advisors Fund, L.P. | |
| Common StockF4 | holding | — | — | — | 786,970 | I | Held by Applied Genomic Technology Capital Fund, L.P. | |
| Common StockF5 | holding | — | — | — | 441,072 | I | Held by Flagship Ventures Fund 2007, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.6006, inclusive. The reporting person undertakes to provide to BG Medicine, Inc., any security holder of BG Medicine, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to 0.6006, inclusive.
- F3Noubar B. Afeyan, Ph.D. is the general partner of Atlast LP and may be deemed to beneficially own the securities held by Atlast LP. Dr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- F4NewcoGen Group, Inc. ("NG") is the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. ("AGTCA") and Applied Genomics Technology Capital Fund, L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar B. Afeyan, Ph.D. is the director of Flagship and may be deemed to beneficially own the securities held by the AGTC Funds. Dr. Afeyan disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- F5Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Dr. Afeyan and Mr. Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.